plat

(redirected from tissue plasminogen activator)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to tissue plasminogen activator: streptokinase

plat

A plan or survey map of a parcel of land.Developers file subdivision plats showing block and lot numbers, the dimensions and locations of individual lots, and the dimensions and locations of dedicated streets. Legal descriptions for properties within the subdivision are then made by reference to the recorded plat,such as “Lot 2,Block 3 of Harper Downs II as recorded in Plat Book 213,Page 82, of the Judge of Probate of Jefferson County,Alabama.”

References in periodicals archive ?
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomized controlled trial.
Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
American Stroke Association Recommendations for Tissue Plasminogen Activator Utilization Contraindications for Tissue Plasminogen Activator Treatment (Adams et al.
Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest.
Washington, February 20 (ANI): Scientists presenting a study at the American Stroke Association's International Stroke Conference in San Diego revealed that an experimental therapy using tiny bubbles activated by transcranial Doppler (TCD) ultrasound, combined with the clot busting drug tissue plasminogen activator (tPA), might prove more effective than tPA alone in treating patients suffering from ischemic stroke.
None received the powerful clot-busting drug called tissue plasminogen activator (tPA), since it wasn't approved for use in Israel at the time.
Embolectomy patients often present after the 3-hour tissue plasminogen activator time window or are otherwise ineligible for intravenous tissue plasminogen activator.
Desmoteplase has several potential advantages over tissue plasminogen activator (TPA).
Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis.
Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.
Development of new treatment options to reduce vasospasm such as the use of tirilizad or tissue plasminogen activator may ultimately reduce the ICU stay and thus the cost.